Australian Gonococcal Surveillance Programme annual report, 2010

Authors

  • Australian Gonococcal Surveillance Programme
  • Monica Lahra Department of Microbiology, SEALS, The Prince of Wales Hospital, Randwick, NSW 2031

DOI:

https://doi.org/10.33321/cdi.2011.35.21

Keywords:

antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeae

Abstract

The Australian Gonococcal Surveillance Programme monitors antibiotic susceptibility testing of Neisseria gonorrhoeae isolated in all states and territories. In 2010 the in vitro susceptibility of 3,997 isolates of gonococci from public and private sector sources was determined by standardised methods. Varying antibiotic susceptibility patterns were again reported across jurisdictions and regions. Resistance to the penicillins nationally was 29% and, with the exception of the Northern Territory, ranged from 22% in Queensland to 42% in Victoria. Quinolone resistance, most at high minimal inhibitory concentration (MIC) levels, was 35% nationally (excepting the Northern Territory), ranging from 28% in Queensland to 44% in Victoria. Decreased susceptibility to ceftriaxone (MIC 0.06 mg/L or more), was found nationally in 4.8% of isolates. There has not been an isolate of N. gonorrhoeae with an MIC value greater than 0.125 mg/L reported in Australia. Nationally, all isolates remained sensitive to spectinomycin. Azithromycin surveillance was performed in New South Wales, Queensland, Western Australia, the Northern Territory and South Australia, and resistance was found in low numbers of gonococci with MIC values up to 16 mg/L. In larger urban centres the ratio of male to female cases was high, and rectal and pharyngeal isolates were common in men. In other centres, and in rural Australia, the male to female ratio of cases was lower, and most isolates were from the genital tract. Commun Dis Intell 2011;35(3):229–236.

Downloads

Download data is not yet available.

References

World Health Organization. Fact sheet: Emergence of multi-drug resistant Neisseria gonorrhoeae. Accessed on 19 July 2011. Available from: http://whqlibdoc.who.int/hq/2011/WHO_RHR_11.14_eng.pdf

Australian Government Department of Health and Ageing. National Notifiable Diseases Surveillance System data for meningococcal disease. Report number 3: Notifications of selected disease by state and territory and year. [online]. Accessed on 19 July 2011. Available from: http://www9.health.gov.au/cda/source/Rpt_3.cfm

Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multi-drug- and extensively drug resistant Neisseria gonorrhoea. Expert Rev Anti Infect Ther 2009;7(7):821–834.

Tapsall JW, Limnios EA, Murphy DM, Australian Gonococcal Surveillance Programme. Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997–2006. J Antimicrob Chemother 2008;61(1):150–155.

Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009;85(4):256–258.

Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007;13(8):1275–1277.

Lo JY, Ho KM, Leung AO, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008;52(10):3564–3567.

Tapsall JW, Read P, Carmody C, Bourne C, Ray S, Limnios A, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009;58(Pt 5):683–687.

Tapsall JW. Monitoring antimicrobial resistance for public health action. Commun Dis Intell 2003;27 Suppl:S70–S74.

Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008;148(8):606–613.

Australian Gonococcal Surveillance Programme. Penicillin sensitivity of gonococci in Australia: the development of an Australian Gonococcal Surveillance Programme. Br J Vener Dis 1984;60(4):226–230.

Australian Gonococcal Surveillance Programme. Annual report of the Australian Gonococcal Surveillance Programme, 2007. Commun Dis Intell 2008;32(2):227–231.

Tapsall J, National Neisseria Network of Australia. Antimicrobial testing and applications in the pathogenic Neisseria. In: Merlino J, ed., Antimicrobial susceptibility testing: methods and practices with an Australian perspective. Australian Society for Microbiology, Sydney, 2004. pp 175–188.

Australian Gonococcal Surveillance Programme. Use of a quality assurance scheme in a long-term multicentric study of antibiotic susceptibility of Neisseria gonorrhoeae. Genitourin Med 1990;66(1):437–444.

WHO Collaborating Centre for STD, Sydney. Rationale and applications for the current (2008) WHO panel of Neisseria gonorrhoeae for antimicrobial resistance surveillance for public health purposes, and instructions for their use. Technical document D007-0408-1#1 2008.

Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009;63(6):1142–1151.

WHO Western Pacific and South East Asian Gonococcal Antimicrobial Surveillance Programmes. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009. Commun Dis Intell 2011;35(1):2–7.

Tapsall JW, Ray S, Limnios A. Characteristics and population dynamics of mosaic penA allele-containing Neisseria gonorrhoeae isolated in Sydney, Australia, 2007–2008. Antimicrob Agents Chemother 2010;54(1):554–556.

Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW. Diversity of penA alterations and subtypes of Neisseria gonorrhoeae less susceptible to ceftriaxone from Sydney, Australia. Antimicrob Agents Chemother 2007;51(9):3111–3116.

Whiley DM, Goire N, Lambert SB, Ray S, Limnios EA, Nissen MD, et al. Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S, P551L in the gonococcal penicillin-binding protein 2. J Antimicrob Chemother 2010;65(8):1615–1618.

Newman LM, Moran JS, Workowaski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007;44 Suppl 3:S84–S101.

Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 2009;22(1):87–89.

Tapsall JW. Multi-resistant Neisseria gonorrhoea. CMAJ 2009;180(3):268–269.

Downloads

Published

01/09/11

How to Cite

Australian Gonococcal Surveillance Programme, and Monica Lahra. 2011. “Australian Gonococcal Surveillance Programme Annual Report, 2010”. Communicable Diseases Intelligence 35 (September):229-36. https://doi.org/10.33321/cdi.2011.35.21.

Most read articles by the same author(s)

1 2 3 4 > >>